John Kaliszak, MD
Emergency Medicine · Decatur, ALNPI 1932200680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 38.8% of the total. Reporting peaked in 2019 at $608 and has fallen 96.9% since, to $19 in 2025. Among emergency medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$658
- Novo Nordisk$265
- Daiichi Sankyo Inc.$190
- Protega Pharmaceutials Inc$91
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$70
- Amgen$64
- plus $359 from 13 others
What the payments were for
- Food & beverage$1,67499%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 45 | $658 |
| Novo Nordisk | 15 | $265 |
| Daiichi Sankyo Inc. | 6 | $190 |
| Protega Pharmaceutials Inc | 3 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Amgen | 5 | $64 |
| Kaleo, Inc. | 4 | $64 |
| Pfizer | 4 | $49 |
| Indivior Inc. | 3 | $44 |
| MDD US Operations, LLC | 2 | $26 |
| Fidia Pharma USA Inc. | 1 | $25 |
| Medtronic | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Almatica Pharma LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Morphabond ER$125
How this compares
$1,695 in reported general payments places this provider in the 95th percentile of 565 emergency medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 192 | $120,737 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,944 | $82,459 |
| OxycontinOxycodone Hcl | 111 | $61,213 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,586 | $50,709 |
| Morphine Sulfate ErMorphine Sulfate | 1,057 | $27,422 |
| Gabapentin | 1,292 | $13,847 |
| Pregabalin | 561 | $11,631 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 79 | $11,590 |
| Oxycodone Hcl | 634 | $8,398 |
| Hydrocodone Bitartrate ErHydrocodone Bitartrate | 18 | $8,221 |
| Tramadol Hcl ErTramadol Hcl | 82 | $6,170 |
| Tizanidine Hcl | 531 | $5,553 |
| Methocarbamol | 301 | $3,041 |
| Lidocaine | 11 | $2,986 |
| Naloxone Hcl | 32 | $2,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $658 | $120,737192 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate | $21 | $13,900171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 emergency medicine providers in Alabama.
Other emergency medicine in Decatur
- Mark MitchellAtmore$309K
- James GalbraithBirmingham$74K
- Lauren WalterBirmingham$64K
- Mark ChristensenBoaz$31K
- Lisa Moreno-WaltonMobile$23K
- Jeremy TownsPell City$10K
- Malika AryanpureNorthport$9K
- Jorge AlsipMobile$8K
- Brian HassaniMontgomery$4K
- Maxwell ThompsonBirmingham$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.